Kyverna Therapeutics Inc. KYTX

NAS: KYTX | ISIN: US5019761049 6/05/2024

13,96 USD (-8,46%)

(-8,46%) 6/05/2024

Grafiek Kyverna Therapeutics Inc.

Grafiek Kyverna Therapeutics Inc.

1 dag1d -8,46%
1 week1w -7,79%
1 maand1m -40,03%
3 maanden3m -53,47%
6 maanden6m -53,47%
1 jaar1j -53,47%
5 jaar5j -53,47%

Kyverna Therapeutics Inc. in het nieuws

Toon enkel gratis nieuws

11 april 2024 · Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases · Persbericht

29 maart 2024 · First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med · Persbericht

26 maart 2024 · Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results · Persbericht

8 maart 2024 · Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis · Persbericht

12 februari 2024 · Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares · Persbericht

8 februari 2024 · Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering · Persbericht

Aandelen Kyverna Therapeutics Inc.

Beurswaarde: 657,51 miljoen USD

Effecten: 43,12 miljoen

Beta: 0,05

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe